Botulinum neurotoxin as early treatment in acute-onset lesional hemiballism
Background Hemiballism (HB) and hemichorea (HC) are the most frequent secondary movement disorders, usually caused by cerebrovascular diseases. In only a minority of cases, these involuntary movements are not self-limited, and they may severely compromise patients’ quality of life, so that symptomat...
Gespeichert in:
Veröffentlicht in: | Neurological sciences 2024-07, Vol.45 (7), p.3509-3511 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 3511 |
---|---|
container_issue | 7 |
container_start_page | 3509 |
container_title | Neurological sciences |
container_volume | 45 |
creator | Di Rauso, Giulia Orlandi, Niccolò Jacopetti, Marco Bigliardi, Guido Antonelli, Francesca Meletti, Stefano Rispoli, Vittorio |
description | Background
Hemiballism (HB) and hemichorea (HC) are the most frequent secondary movement disorders, usually caused by cerebrovascular diseases. In only a minority of cases, these involuntary movements are not self-limited, and they may severely compromise patients’ quality of life, so that symptomatic treatments are required. Typical and atypical neuroleptics as well as tetrabenazine are considered therapies of choice. However, anecdotal reports of antiseizures medications and botulinum neurotoxin injection effectiveness have been described.
Methods
We described a case of severely disabling acute-onset lesional HB/HC, where high dosage of first- and second-line therapies was contraindicated due to patient’s comorbidities.
Results
After botulin neurotoxin (BoNT) injections in his left upper limb muscles (biceps brachii, triceps brachii, teres major, and deltoid), the patient experienced gradual reduction of hyperkinetic movements. The gradual discontinuation of topiramate (TPM) did not worsen the clinical picture.
Discussion
The reduction of hyperkinetic movements led to rhabdomyolysis resolution as well as cutaneous injuries healing with renal function improvement, so that the patient was able to be eligible for rehabilitation, which was prevented by HB/HC itself. The clinical improvement was consistent with BoNT pharmacokinetic. The administration of BoNT early after the onset of lesional HB/HC remarkably modified the clinical management and drove toward comorbidities resolution and rehabilitation.
Conclusion
The present case highlights the effectiveness of unconventional therapeutic options in disabling acute onset lesional HB/HC when first-line therapies are contraindicated. Particularly, this report may encourage BoNT application in the early stage of movement disorder emergencies. |
doi_str_mv | 10.1007/s10072-024-07465-0 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3022567154</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3067592768</sourcerecordid><originalsourceid>FETCH-LOGICAL-c326t-66c27a253ec07a0fbf619f2ee770d0b11e34329f0f4104bcc4810ccf282612f53</originalsourceid><addsrcrecordid>eNp9kMtKxTAQhoMoHm8v4EIKbtxUJ5cm7VLFGwpudB3SONEe0kaTFPTt7fEcFVy4yYTMN_-Ej5B9CscUQJ2kxclKYKIEJWRVwhrZolUDJReqXl_daa3EjGynNAcAKijfJDNeV6KuG7FFbs9CHn03jH0x4BhDDu_dUJhUoIn-o8gRTe5xyMXi1Y4ZyzAkzIXH1IXB-OIF-6413nep3yUbzviEe6u6Qx4vLx7Or8u7-6ub89O70nImcymlZcqwiqMFZcC1TtLGMUSl4AlaSpELzhoHTlAQrbWipmCtYzWTlLmK75CjZe5rDG8jpqz7Lln03gwYxqQ5MFZJRSsxoYd_0HkY4_TvBSVV1TAl64liS8rGkFJEp19j15v4oSnohWS9VK0n1fpLtYZp6GAVPbY9Pv2MfLudAL4E0tQanjH-7v4n9hPHy4jl</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3067592768</pqid></control><display><type>article</type><title>Botulinum neurotoxin as early treatment in acute-onset lesional hemiballism</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Di Rauso, Giulia ; Orlandi, Niccolò ; Jacopetti, Marco ; Bigliardi, Guido ; Antonelli, Francesca ; Meletti, Stefano ; Rispoli, Vittorio</creator><creatorcontrib>Di Rauso, Giulia ; Orlandi, Niccolò ; Jacopetti, Marco ; Bigliardi, Guido ; Antonelli, Francesca ; Meletti, Stefano ; Rispoli, Vittorio</creatorcontrib><description>Background
Hemiballism (HB) and hemichorea (HC) are the most frequent secondary movement disorders, usually caused by cerebrovascular diseases. In only a minority of cases, these involuntary movements are not self-limited, and they may severely compromise patients’ quality of life, so that symptomatic treatments are required. Typical and atypical neuroleptics as well as tetrabenazine are considered therapies of choice. However, anecdotal reports of antiseizures medications and botulinum neurotoxin injection effectiveness have been described.
Methods
We described a case of severely disabling acute-onset lesional HB/HC, where high dosage of first- and second-line therapies was contraindicated due to patient’s comorbidities.
Results
After botulin neurotoxin (BoNT) injections in his left upper limb muscles (biceps brachii, triceps brachii, teres major, and deltoid), the patient experienced gradual reduction of hyperkinetic movements. The gradual discontinuation of topiramate (TPM) did not worsen the clinical picture.
Discussion
The reduction of hyperkinetic movements led to rhabdomyolysis resolution as well as cutaneous injuries healing with renal function improvement, so that the patient was able to be eligible for rehabilitation, which was prevented by HB/HC itself. The clinical improvement was consistent with BoNT pharmacokinetic. The administration of BoNT early after the onset of lesional HB/HC remarkably modified the clinical management and drove toward comorbidities resolution and rehabilitation.
Conclusion
The present case highlights the effectiveness of unconventional therapeutic options in disabling acute onset lesional HB/HC when first-line therapies are contraindicated. Particularly, this report may encourage BoNT application in the early stage of movement disorder emergencies.</description><identifier>ISSN: 1590-1874</identifier><identifier>ISSN: 1590-3478</identifier><identifier>EISSN: 1590-3478</identifier><identifier>DOI: 10.1007/s10072-024-07465-0</identifier><identifier>PMID: 38548894</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Antipsychotics ; Botulinum toxin ; Botulinum Toxins, Type A - administration & dosage ; Botulinum Toxins, Type A - therapeutic use ; Brief Communication ; Cerebrovascular diseases ; Chorea - drug therapy ; Comorbidity ; Contraindications ; Dyskinesias - drug therapy ; Dyskinesias - etiology ; Humans ; Male ; Medical treatment ; Medicine ; Medicine & Public Health ; Middle Aged ; Movement disorders ; Muscles ; Neurology ; Neuromuscular Agents - administration & dosage ; Neuromuscular Agents - therapeutic use ; Neuroradiology ; Neurosurgery ; Patients ; Pharmacokinetics ; Psychiatry ; Quality of life ; Rehabilitation ; Renal function ; Rhabdomyolysis ; Tetrabenazine ; Topiramate ; Vascular diseases ; Wound healing</subject><ispartof>Neurological sciences, 2024-07, Vol.45 (7), p.3509-3511</ispartof><rights>Fondazione Società Italiana di Neurologia 2024</rights><rights>2024. Fondazione Società Italiana di Neurologia.</rights><rights>Fondazione Società Italiana di Neurologia 2024.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c326t-66c27a253ec07a0fbf619f2ee770d0b11e34329f0f4104bcc4810ccf282612f53</cites><orcidid>0000-0001-6728-8481 ; 0000-0003-0334-539X ; 0000-0001-5312-7206 ; 0000-0001-7159-9311 ; 0000-0002-5717-7363</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10072-024-07465-0$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10072-024-07465-0$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38548894$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Di Rauso, Giulia</creatorcontrib><creatorcontrib>Orlandi, Niccolò</creatorcontrib><creatorcontrib>Jacopetti, Marco</creatorcontrib><creatorcontrib>Bigliardi, Guido</creatorcontrib><creatorcontrib>Antonelli, Francesca</creatorcontrib><creatorcontrib>Meletti, Stefano</creatorcontrib><creatorcontrib>Rispoli, Vittorio</creatorcontrib><title>Botulinum neurotoxin as early treatment in acute-onset lesional hemiballism</title><title>Neurological sciences</title><addtitle>Neurol Sci</addtitle><addtitle>Neurol Sci</addtitle><description>Background
Hemiballism (HB) and hemichorea (HC) are the most frequent secondary movement disorders, usually caused by cerebrovascular diseases. In only a minority of cases, these involuntary movements are not self-limited, and they may severely compromise patients’ quality of life, so that symptomatic treatments are required. Typical and atypical neuroleptics as well as tetrabenazine are considered therapies of choice. However, anecdotal reports of antiseizures medications and botulinum neurotoxin injection effectiveness have been described.
Methods
We described a case of severely disabling acute-onset lesional HB/HC, where high dosage of first- and second-line therapies was contraindicated due to patient’s comorbidities.
Results
After botulin neurotoxin (BoNT) injections in his left upper limb muscles (biceps brachii, triceps brachii, teres major, and deltoid), the patient experienced gradual reduction of hyperkinetic movements. The gradual discontinuation of topiramate (TPM) did not worsen the clinical picture.
Discussion
The reduction of hyperkinetic movements led to rhabdomyolysis resolution as well as cutaneous injuries healing with renal function improvement, so that the patient was able to be eligible for rehabilitation, which was prevented by HB/HC itself. The clinical improvement was consistent with BoNT pharmacokinetic. The administration of BoNT early after the onset of lesional HB/HC remarkably modified the clinical management and drove toward comorbidities resolution and rehabilitation.
Conclusion
The present case highlights the effectiveness of unconventional therapeutic options in disabling acute onset lesional HB/HC when first-line therapies are contraindicated. Particularly, this report may encourage BoNT application in the early stage of movement disorder emergencies.</description><subject>Antipsychotics</subject><subject>Botulinum toxin</subject><subject>Botulinum Toxins, Type A - administration & dosage</subject><subject>Botulinum Toxins, Type A - therapeutic use</subject><subject>Brief Communication</subject><subject>Cerebrovascular diseases</subject><subject>Chorea - drug therapy</subject><subject>Comorbidity</subject><subject>Contraindications</subject><subject>Dyskinesias - drug therapy</subject><subject>Dyskinesias - etiology</subject><subject>Humans</subject><subject>Male</subject><subject>Medical treatment</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Movement disorders</subject><subject>Muscles</subject><subject>Neurology</subject><subject>Neuromuscular Agents - administration & dosage</subject><subject>Neuromuscular Agents - therapeutic use</subject><subject>Neuroradiology</subject><subject>Neurosurgery</subject><subject>Patients</subject><subject>Pharmacokinetics</subject><subject>Psychiatry</subject><subject>Quality of life</subject><subject>Rehabilitation</subject><subject>Renal function</subject><subject>Rhabdomyolysis</subject><subject>Tetrabenazine</subject><subject>Topiramate</subject><subject>Vascular diseases</subject><subject>Wound healing</subject><issn>1590-1874</issn><issn>1590-3478</issn><issn>1590-3478</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtKxTAQhoMoHm8v4EIKbtxUJ5cm7VLFGwpudB3SONEe0kaTFPTt7fEcFVy4yYTMN_-Ej5B9CscUQJ2kxclKYKIEJWRVwhrZolUDJReqXl_daa3EjGynNAcAKijfJDNeV6KuG7FFbs9CHn03jH0x4BhDDu_dUJhUoIn-o8gRTe5xyMXi1Y4ZyzAkzIXH1IXB-OIF-6413nep3yUbzviEe6u6Qx4vLx7Or8u7-6ub89O70nImcymlZcqwiqMFZcC1TtLGMUSl4AlaSpELzhoHTlAQrbWipmCtYzWTlLmK75CjZe5rDG8jpqz7Lln03gwYxqQ5MFZJRSsxoYd_0HkY4_TvBSVV1TAl64liS8rGkFJEp19j15v4oSnohWS9VK0n1fpLtYZp6GAVPbY9Pv2MfLudAL4E0tQanjH-7v4n9hPHy4jl</recordid><startdate>20240701</startdate><enddate>20240701</enddate><creator>Di Rauso, Giulia</creator><creator>Orlandi, Niccolò</creator><creator>Jacopetti, Marco</creator><creator>Bigliardi, Guido</creator><creator>Antonelli, Francesca</creator><creator>Meletti, Stefano</creator><creator>Rispoli, Vittorio</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6728-8481</orcidid><orcidid>https://orcid.org/0000-0003-0334-539X</orcidid><orcidid>https://orcid.org/0000-0001-5312-7206</orcidid><orcidid>https://orcid.org/0000-0001-7159-9311</orcidid><orcidid>https://orcid.org/0000-0002-5717-7363</orcidid></search><sort><creationdate>20240701</creationdate><title>Botulinum neurotoxin as early treatment in acute-onset lesional hemiballism</title><author>Di Rauso, Giulia ; Orlandi, Niccolò ; Jacopetti, Marco ; Bigliardi, Guido ; Antonelli, Francesca ; Meletti, Stefano ; Rispoli, Vittorio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c326t-66c27a253ec07a0fbf619f2ee770d0b11e34329f0f4104bcc4810ccf282612f53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antipsychotics</topic><topic>Botulinum toxin</topic><topic>Botulinum Toxins, Type A - administration & dosage</topic><topic>Botulinum Toxins, Type A - therapeutic use</topic><topic>Brief Communication</topic><topic>Cerebrovascular diseases</topic><topic>Chorea - drug therapy</topic><topic>Comorbidity</topic><topic>Contraindications</topic><topic>Dyskinesias - drug therapy</topic><topic>Dyskinesias - etiology</topic><topic>Humans</topic><topic>Male</topic><topic>Medical treatment</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Movement disorders</topic><topic>Muscles</topic><topic>Neurology</topic><topic>Neuromuscular Agents - administration & dosage</topic><topic>Neuromuscular Agents - therapeutic use</topic><topic>Neuroradiology</topic><topic>Neurosurgery</topic><topic>Patients</topic><topic>Pharmacokinetics</topic><topic>Psychiatry</topic><topic>Quality of life</topic><topic>Rehabilitation</topic><topic>Renal function</topic><topic>Rhabdomyolysis</topic><topic>Tetrabenazine</topic><topic>Topiramate</topic><topic>Vascular diseases</topic><topic>Wound healing</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Di Rauso, Giulia</creatorcontrib><creatorcontrib>Orlandi, Niccolò</creatorcontrib><creatorcontrib>Jacopetti, Marco</creatorcontrib><creatorcontrib>Bigliardi, Guido</creatorcontrib><creatorcontrib>Antonelli, Francesca</creatorcontrib><creatorcontrib>Meletti, Stefano</creatorcontrib><creatorcontrib>Rispoli, Vittorio</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Neurological sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Di Rauso, Giulia</au><au>Orlandi, Niccolò</au><au>Jacopetti, Marco</au><au>Bigliardi, Guido</au><au>Antonelli, Francesca</au><au>Meletti, Stefano</au><au>Rispoli, Vittorio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Botulinum neurotoxin as early treatment in acute-onset lesional hemiballism</atitle><jtitle>Neurological sciences</jtitle><stitle>Neurol Sci</stitle><addtitle>Neurol Sci</addtitle><date>2024-07-01</date><risdate>2024</risdate><volume>45</volume><issue>7</issue><spage>3509</spage><epage>3511</epage><pages>3509-3511</pages><issn>1590-1874</issn><issn>1590-3478</issn><eissn>1590-3478</eissn><abstract>Background
Hemiballism (HB) and hemichorea (HC) are the most frequent secondary movement disorders, usually caused by cerebrovascular diseases. In only a minority of cases, these involuntary movements are not self-limited, and they may severely compromise patients’ quality of life, so that symptomatic treatments are required. Typical and atypical neuroleptics as well as tetrabenazine are considered therapies of choice. However, anecdotal reports of antiseizures medications and botulinum neurotoxin injection effectiveness have been described.
Methods
We described a case of severely disabling acute-onset lesional HB/HC, where high dosage of first- and second-line therapies was contraindicated due to patient’s comorbidities.
Results
After botulin neurotoxin (BoNT) injections in his left upper limb muscles (biceps brachii, triceps brachii, teres major, and deltoid), the patient experienced gradual reduction of hyperkinetic movements. The gradual discontinuation of topiramate (TPM) did not worsen the clinical picture.
Discussion
The reduction of hyperkinetic movements led to rhabdomyolysis resolution as well as cutaneous injuries healing with renal function improvement, so that the patient was able to be eligible for rehabilitation, which was prevented by HB/HC itself. The clinical improvement was consistent with BoNT pharmacokinetic. The administration of BoNT early after the onset of lesional HB/HC remarkably modified the clinical management and drove toward comorbidities resolution and rehabilitation.
Conclusion
The present case highlights the effectiveness of unconventional therapeutic options in disabling acute onset lesional HB/HC when first-line therapies are contraindicated. Particularly, this report may encourage BoNT application in the early stage of movement disorder emergencies.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>38548894</pmid><doi>10.1007/s10072-024-07465-0</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0001-6728-8481</orcidid><orcidid>https://orcid.org/0000-0003-0334-539X</orcidid><orcidid>https://orcid.org/0000-0001-5312-7206</orcidid><orcidid>https://orcid.org/0000-0001-7159-9311</orcidid><orcidid>https://orcid.org/0000-0002-5717-7363</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1590-1874 |
ispartof | Neurological sciences, 2024-07, Vol.45 (7), p.3509-3511 |
issn | 1590-1874 1590-3478 1590-3478 |
language | eng |
recordid | cdi_proquest_miscellaneous_3022567154 |
source | MEDLINE; Springer Nature - Complete Springer Journals |
subjects | Antipsychotics Botulinum toxin Botulinum Toxins, Type A - administration & dosage Botulinum Toxins, Type A - therapeutic use Brief Communication Cerebrovascular diseases Chorea - drug therapy Comorbidity Contraindications Dyskinesias - drug therapy Dyskinesias - etiology Humans Male Medical treatment Medicine Medicine & Public Health Middle Aged Movement disorders Muscles Neurology Neuromuscular Agents - administration & dosage Neuromuscular Agents - therapeutic use Neuroradiology Neurosurgery Patients Pharmacokinetics Psychiatry Quality of life Rehabilitation Renal function Rhabdomyolysis Tetrabenazine Topiramate Vascular diseases Wound healing |
title | Botulinum neurotoxin as early treatment in acute-onset lesional hemiballism |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T22%3A18%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Botulinum%20neurotoxin%20as%20early%20treatment%20in%20acute-onset%20lesional%20hemiballism&rft.jtitle=Neurological%20sciences&rft.au=Di%20Rauso,%20Giulia&rft.date=2024-07-01&rft.volume=45&rft.issue=7&rft.spage=3509&rft.epage=3511&rft.pages=3509-3511&rft.issn=1590-1874&rft.eissn=1590-3478&rft_id=info:doi/10.1007/s10072-024-07465-0&rft_dat=%3Cproquest_cross%3E3067592768%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3067592768&rft_id=info:pmid/38548894&rfr_iscdi=true |